0001209191-20-039025.txt : 20200625 0001209191-20-039025.hdr.sgml : 20200625 20200625200323 ACCESSION NUMBER: 0001209191-20-039025 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200103 FILED AS OF DATE: 20200625 DATE AS OF CHANGE: 20200625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Abdollahian Neil CENTRAL INDEX KEY: 0001678223 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 20990648 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-01-03 2020-01-06 0 0001610618 Cidara Therapeutics, Inc. CDTX 0001678223 Abdollahian Neil 6310 NANCY RIDGE DR SUITE 101 SAN DIEGO CA 92121 0 1 0 0 Chief Business Officer Common Stock 2020-01-03 4 S 0 940 3.42 D 50308 D This amendment is being filed to correct the number of shares sold which were underreported by 940 shares (i.e. a total of 3,280 shares were sold rather than 2,340) and to correct the end of period holdings to reduce such amount by 940 shares. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 12/31/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2019. /s/ Jessica Oien, Attorney-in-fact 2020-06-23